Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim's Diabetes Pipeline Continues to Advance as the Company Announces Conclusion of Robust Phase III Clinical Program for linagliptin
Published in Drug Law Weekly, October 13th, 2009
Boehringer Ingelheim Pharmaceuticals, Inc. announced the conclusion of the linagliptin pivotal Phase III clinical trials, including more than 4,000 patients in 40 countries worldwide. Phase II data for linagliptin were presented earlier this year at the annual American Diabetes Association (ADA) Scientific Sessions. Full results from the Phase III trials will be presented at international scientific congresses in 2010 and beyond.
"Many diabetes patients do not achieve adequate blood sugar control with currently available medications, so there is a high degree of unmet medical need in this therapeutic area," said Dr. Thor Voigt, senior vice president, Medicine and Drug...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2009-10-13)
More Articles from Drug Law Weekly
- Alexza Pharmaceuticals, Inc.
Alexza to Raise $19.7 Million in Private Placement - Bionovo, Inc.
Bionovo Announces Pricing of Securities Offering - Biopharmaceuticals
Keryx Biopharmaceuticals, Inc. to Raise $20 Million in Registered Direct Offering - Center for Justice & Democracy
National Consumer Groups Announce Urgent New Ads Asking Congress to Oppose Medical Malpractice Limits - Clinical Trial Research
More Than 100 Organizations Support Bill to Boost Participation in Clinical Trials for Rare Diseases - Emergency Medicine
Stephen W. Borron, M.D., Named Medical Editor-In-Chief of ToxED - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
